CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

NCT07361003 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT464

EST. COMPLETION2028-01

Conditions

Refractory Metastatic Colorectal Cancer

Interventions

Suvemcitug injection, trifluridine/tipiracil tabletsSuvemcitug placebo injection, trifluridine/tipiracil tablets

Study details

SPONSORJiangsu Simcere Pharmaceutical Co., Ltd.

START DATE2025-11-12

Related company profiles

Simcere Pharmaceutical Group

2096.HK

Primary source

ClinicalTrials.gov record NCT07361003 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT07361003
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record